Drug intelligence / Profile preview

JM295

Development stage: Preclinical
Lead developer: JMackem
Modality: Small Molecules

Overview

JM295 is a small molecule therapeutic candidate being developed by JMackem for the treatment of chronic pain. It functions as a dual-action agent, exhibiting antagonist activity against serotonin (5-HT) receptors and inhibiting the glycine transporter 2 (GlyT2). This dual mechanism is intended to modulate pain signaling within the central nervous system; GlyT2 inhibition increases synaptic glycine levels to enhance inhibitory neurotransmission in the spinal cord, while serotonin receptor antagonism targets the descending pain modulatory system. JM295 is currently in the preclinical stage of development.

Other names: 5-HT + Gly2T antagonist

Targets

5-HT (Serotonin receptors)GlyT2 (Glycine transporter type 2)

Beyond the preview

Go deeper on JM295.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JM295.

Explore the full profile